𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Antibodies against human cell receptors, CD36, CD41a, and CD62P crossreact with porcine platelets

✍ Scribed by Delgado, Angel V. ;Alexander, Stefan L. ;McManus, Albert T. ;Pusateri, Anthony E.


Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
184 KB
Volume
56B
Category
Article
ISSN
0196-4763

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Background

A limitation in platelet study has been the availability of platelet function–specific membrane receptor antibodies for use in the various animal species that are currently used in the study of hemostasis and other phenomena.

Methods

Platelets were isolated from human and porcine blood. Resting and activated platelets were incubated with antibodies against the human cell surface receptors CD36 (clone CB38), CD41a (clone HIP8), CD62P (clone AK4), and CD63 (clone H5C6). Antibody titration and ligand blocking studies also were performed.

Results

Binding of anti‐CD41a and anti‐CD62P were similar for human and porcine platelets in percentage of platelets labeled and in number of receptors per cell. Binding of anti‐CD36 was similar between species, with fewer receptors present in porcine cells. Anti‐CD63 and anti‐CD107a did not bind specifically to porcine platelets.

Conclusion

The anti‐CD36, anti‐CD41a, and anti‐CD62P antibodies studied crossreact with porcine platelets and will be useful in the investigation of platelet function in porcine models. Cytometry Part B (Clin. Cytometry) 56B:62–67, 2003. Published 2003 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Immunotoxins constructed with anti-CD25
✍ Andreas Engert; Gary Martin; Peter Amlot; John Wijdenes; Volker Diehl; Philip Th 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 French ⚖ 867 KB

## Abstract Twenty‐three monoclonal antibodies (MAbs) against the IL‐2 receptor α‐chain (CD25) were evaluated as ricin A‐chain immunotoxins for the treatment of Hodgkin's disease. Primary screening used an indirect assay in which the cells were treated with the test antibody followed by a Fab immun